Hereditary Hemochromatosis When Therapeutic Phlebotomy Cannot Be Performed: Second-Line Treatment
Therapeutic phlebotomy is the first-line approach for iron depletion in hereditary hemochromatosis. When phlebotomy is not possible, an alternative second-line strategy must be considered to address iron overload.
The first-line intervention — therapeutic phlebotomy — aims to reduce serum ferritin to 50 µg/L during the induction phase and to maintain it in the 50–100 µg/L range during maintenance. When phlebotomy cannot be performed, these iron-reduction targets cannot be reached through the standard route, and a second-line approach becomes necessary.
Iron chelation therapy is a second-line option, initiated after careful consideration of the risk-benefit ratio. The full protocol specifies the preferred oral chelating agent, patient selection criteria, contraindications, and monitoring requirements.
If phlebotomy is not possible, iron chelation therapy can be started after careful consideration of risk-benefit ratio.
Most evidence in haemochromatosis pertains to oral deferasirox (DFX) as a possible second-line option, which is effective in removing iron, but evidence is weak and DFX should not be used in patients with advanced liver disease.
A number of patients on the 15 mg/kg dose experienced side effects and the authors recommend a starting dose of 10 mg/kg, which reduced median serum ferritin concentration by 75% over a 48-week period and to <250 ng/ml.
View source ↗